Sökning: LAR1:gu
> Forskningsöversikt
> Chalmers tekniska högskola >
Overproduction of v...
Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
-
- Adiels, Martin, 1976 (författare)
- Gothenburg University,Göteborgs universitet,Wallenberglaboratoriet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Wallenberg Laboratory,Institute of Medicine, Department of Molecular and Clinical Medicine,University of Gothenburg
-
- Olofsson, Sven-Olof, 1947 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Wallenberglaboratoriet,Institute of Medicine, Department of Molecular and Clinical Medicine,Wallenberg Laboratory,University of Gothenburg
-
Taskinen, Marja-Riitta (författare)
-
visa fler...
-
- Borén, Jan, 1963 (författare)
- Gothenburg University,Göteborgs universitet,Wallenberglaboratoriet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Wallenberg Laboratory,Institute of Medicine, Department of Molecular and Clinical Medicine,University of Gothenburg
-
visa färre...
-
(creator_code:org_t)
- 2008
- 2008
- Engelska.
-
Ingår i: Arteriosclerosis, thrombosis, and vascular biology. - 1524-4636 .- 1079-5642. ; 28:7, s. 1225-36
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
https://research.cha...
-
visa färre...
Abstract
Ämnesord
Stäng
- Insulin resistance is a key feature of the metabolic syndrome and often progresses to type 2 diabetes. Both insulin resistance and type 2 diabetes are characterized by dyslipidemia, which is an important and common risk factor for cardiovascular disease. Diabetic dyslipidemia is a cluster of potentially atherogenic lipid and lipoprotein abnormalities that are metabolically interrelated. Recent evidence suggests that a fundamental defect is an overproduction of large very low-density lipoprotein (VLDL) particles, which initiates a sequence of lipoprotein changes, resulting in higher levels of remnant particles, smaller LDL, and lower levels of high-density liporotein (HDL) cholesterol. These atherogenic lipid abnormalities precede the diagnosis of type 2 diabetes by several years, and it is thus important to elucidate the mechanisms involved in the overproduction of large VLDL particles. Here, we review the pathophysiology of VLDL biosynthesis and metabolism in the metabolic syndrome. We also review recent research investigating the relation between hepatic accumulation of lipids and insulin resistance, and sources of fatty acids for liver fat and VLDL biosynthesis. Finally, we briefly discuss current treatments for lipid management of dyslipidemia and potential future therapeutic targets.
Nyckelord
- Antilipemic Agents
- therapeutic use
- Diabetes Mellitus
- Type 2
- etiology
- metabolism
- physiopathology
- prevention & control
- Disease Progression
- Dyslipidemias
- blood
- drug therapy
- metabolism
- Fatty Acids
- metabolism
- Humans
- Insulin Resistance
- Lipoproteins
- VLDL
- blood
- metabolism
- Liver
- metabolism
- Metabolic Syndrome X
- complications
- drug therapy
- metabolism
- physiopathology
- Triglycerides
- metabolism
- Up-Regulation
- prevention & control
Publikations- och innehållstyp
- ref (ämneskategori)
- for (ämneskategori)
Hitta via bibliotek
Till lärosätets databas